Picture [LSUS] – The Business Web Portal 650x65px
Person › Details

Thomas Schirrmann (Yumab GmbH)

Schirrmann, Thomas (Yumab GmbH 201907 Managing Director)


Organisation Organisation Yumab GmbH
Products Product antibody technology
  Product 2 antibody library

Yumab GmbH. (7/22/19). "Press Release: Yumab Announces New Research and Collaboration Agreement with Merck". Braunschweig.

YUMAB GmbH, a privately-held German biotechnology company, and Merck, a leading science and technology company, have signed a research and collaboration agreement on July 22nd, 2019. Within the scope of this cooperation, Merck’s Healthcare business will complement its own drug discovery efforts by utilizing YUMAB’s expertise, its comprehensive antibody libraries and its established technology platform to generate novel therapeutic antibodies. YUMAB welcomes the opportunity to adjust its platform and technologies to the needs of a global pharmaceutical company. Financial conditions of the agreement were not disclosed. Thomas Schirrmann, CEO of YUMAB, comments: “Since the early days of YUMAB, both companies have collaborated based on a shared commitment to accelerating drug discovery, and we look forward to our continuing collaborations enhanced by this new research effort.”


YUMAB GmbH is a German biotechnology company founded in 2012 by scientists of University Braunschweig based on their long and excellent track record in antibody technologies. YUMAB provides technologies and contract research for the discovery and development of fully human antibodies for all therapeutic fields. In little more than six years, the company has become a global player in human monoclonal antibody development and drives the general trend in the immunotherapy space toward the use of fully human antibodies for immunotherapies. In 2018, YUMAB relocated its headquarter and labs to the Science Campus Braunschweig-South, where the company has new opportunities to thrive in an outstanding scientific infrastructure, collocated with the Helmholtz Centre for Infection Research (HZI). For more information please visit


Dr. Thomas Schirrmann, CEO
Phone: +49 531 481170-0

YUMAB GmbH • Inhoffenstr. 7 • 38124 Braunschweig • Germany

Record changed: 2019-08-07


Picture [LSUS] – The Business Web Portal 650x65px

More documents for Thomas Schirrmann

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [LSA] – The Business Web Portal 650x89px

» top